1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Bioptic Inc.

Bioptic Inc.

TTPEX:6850
30.20
TWD
+0.20
(+0.67%)
1.13BMarket Cap
Bioptic Inc.
TPEX:6850
(Taipei Exchange)

Recent

price

30.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
2.8
4.13
5.04
5.72
6.97
6.9
6.13
- -
- -
Revenue per Share
-0.66
0.1
1.06
1.48
1.85
1.14
0.69
- -
- -
Basic EPS, GAAP
-6.06
-0.46
0.48
0.79
1.89
-3.83
0.73
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.33
0.73
0.16
- -
- -
Dividend per Share
4.47
4.61
5.42
11.09
12.61
13
13.59
- -
13.25
Book Value per Share
4.46
4.6
5.42
11.05
12.57
11.66
12.29
- -
12.92
Tangible Book Value per Share
22
22
25
31
33
33
33
33
33
Basic Weighted Avg Shares
62
92
124
179
231
228
203
- -
- -
Sales/Revenue/Turnover
-25.53
3.97
21.82
24.79
28.09
19.46
9.46
- -
- -
Operating Margin (%)
3
4
5
7
10
15
17
- -
- -
Depreciation Expense
-15
2
26
46
61
38
23
- -
- -
Net Income, GAAP
- -
- -
- -
2.13
19.09
17.11
16.92
- -
- -
Effective Tax Rate (%)
-23.7
2.38
20.98
25.8
26.48
16.54
11.21
- -
- -
Profit Margin (%)
102
104
130
242
289
226
250
- -
274
Working Capital
80
78
82
2
8
86
79
- -
73
LT Debt
149
153
181
375
427
443
462
- -
450
Total Equity
- -
- -
- -
13.32
12.56
7.29
2.87
- -
- -
Return on Invested Capital (%)
- -
- -
- -
13.73
14.45
7.46
4.46
- -
- -
Return on Capital (%)
- -
1.45
15.58
16.87
15.58
8.88
5.16
- -
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
7
- -
8
LT Borrowings
75
- -
71
LT Finance Leases
6
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
1,342
1,317
1,125

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
291
- -
338
Cash, Cash Equivalents & STI
125
- -
188
Accounts Receivable, Net
18
- -
27
Inventories
142
- -
118
Total Current Liabilities
46
- -
63
Payables & Accruals
- -
- -
- -
ST Debt
7
- -
8
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
203
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.69
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.16
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
BiOptic Inc. BiOptic Inc. (6850.TWO), a biotechnology instrumentation company listed on the Taipei Exchange, develops and manufactures innovative scientific instruments and consumables for research and clinical applications utilizing Capillary Gel Electrophoresis (CGE) technology; its core products include bio-fragment analyzers such as the Qsep100, Qsep1 Series, Qsep400 Series, and Gly-Q; PCR thermocyclers including the Qampmini mini-PCR machine; consumables comprising DNA, RNA, protein cartridges, and quantification kits; premix and polymerase PCR reagents; as well as veterinary, human, and food-related testing kits for life science research, clinical diagnostics, pharmaceutical, food industries, animal husbandry, and agriculture. Founded in 2004 and headquartered in New Taipei City, Taiwan, the company maintains R&D, manufacturing, and sales operations in Taiwan alongside support facilities in the US and China, serving customers across more than 50 countries with a focus on easy-to-use, cost-effective solutions for molecular genetic analyses including high-resolution DNA fragment separation, CRISPR/Cas genome editing verification, and high molecular weight DNA quality assessment. BiOptic Inc. continues to innovate through ongoing product expansions and participation in global trade events such as MEDICA 2025 in Düsseldorf, reinforcing its position in biotechnology instrumentation without reported major acquisitions, partnerships, or strategic shifts in the past 1-2 years.